Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a large decline in short interest in October. As of October 15th, there was short interest totalling 1,390,000 shares, a decline of 19.7% from the September 30th total of 1,730,000 shares. Based on an average daily trading volume, of 339,700 shares, the days-to-cover ratio is presently 4.1 days.

Insider Activity

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard bought 173,730 shares of the business's stock in a transaction on Tuesday, July 30th. The stock was purchased at an average cost of $1.30 per share, for a total transaction of $225,849.00. Following the completion of the purchase, the insider now directly owns 13,776,421 shares of the company's stock, valued at approximately $17,909,347.30. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.40% of the company's stock.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter valued at about $39,000. SG Americas Securities LLC lifted its stake in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 13,461 shares during the period. Russell Investments Group Ltd. boosted its holdings in Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company's stock valued at $78,000 after acquiring an additional 61,602 shares during the last quarter. Deuterium Capital Management LLC acquired a new stake in Aclaris Therapeutics during the 1st quarter valued at approximately $99,000. Finally, Marquette Asset Management LLC bought a new position in Aclaris Therapeutics during the 1st quarter worth approximately $104,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on ACRS shares. StockNews.com raised shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, July 25th. HC Wainwright reiterated a "neutral" rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. Seven research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $9.00.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock traded down $0.08 on Monday, hitting $1.61. The stock had a trading volume of 1,159,237 shares, compared to its average volume of 992,909. The stock has a 50 day moving average of $1.20 and a 200 day moving average of $1.20. The firm has a market capitalization of $114.74 million, a P/E ratio of -1.48 and a beta of 0.20. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $5.71.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $2.77 million during the quarter, compared to analysts' expectations of $1.74 million. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. Equities analysts expect that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.